Real-World Effectiveness of Guselkumab for Induction of Remission in Crohn’s Disease: A Prospective Multicentre Cohort Study with Propensity Score-Matched Comparison to Risankizumab

Clicks: 2
ID: 318001
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #16 of 38 articles by views in Crohn s & Colitis 360

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background No head-to-head trials compare selective interleukin-23 inhibitors in Crohn’s disease (CD), leaving clinicians without direct evidence to guide treatment selection. We aimed to evaluate real-world induction effectiveness of guselkumab in CD and perform propensity score-matched (PSM) comparisons against risankizumab. Methods This prospective multicentre study included adults with moderate-to-severe CD initiating guselkumab in the United Arab Emirates. The primary outcome was clinical remission at Week 12 (Harvey-Bradshaw Index <5). Full propensity score matching between guselkumab and risankizumab cohorts controlled for 12 covariates including disease phenotype, baseline endoscopic and biochemical activity, surgical history, and current smoking status. Results Fifty-one guselkumab and 60 risankizumab patients were included. In the guselkumab cohort, 71% were advanced therapy-exposed with a median of 2 prior advanced therapies. At Week 12, clinical remission was achieved in 51% (26/51) and clinical response in 86% (44/51). Median CRP decreased from 8.5 to 3.0 mg/L (p = 0.002) and faecal calprotectin from 216 to 80 ug/g (p < 0.001). Effectiveness was consistent regardless of prior treatment history. On univariable analysis, higher baseline HBI (OR 0.77, p = 0.011), SES-CD (OR 0.87, p = 0.049), and CRP (OR 0.94, p = 0.019) were associated with lower remission likelihood. Maintenance dosing was 100 mg Q8W in 73% and 200 mg Q4W in 27%. PSM analysis demonstrated comparable clinical remission (51% vs 50%, p > 0.9) and clinical response (86% vs 87%, p = 0.87) between guselkumab and risankizumab, with no significant between-group biomarker differences. Conclusions Guselkumab demonstrated robust real-world induction effectiveness comparable to risankizumab across clinical and biochemical outcomes. These findings warrant confirmation in larger, longer-term comparative studies with endoscopic endpoints.
Reference Key
openalex_W7165383029 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Maitha Al Hosani, Noorah Al Hosani, Mohamed Nasir Alzaabi, Maryam AlAhmad, N M Omar, Camille Conde Oribiana, Esraa Ahmed, Ishtiaq Ahmed, Kishor Kumar, Sofia Hanif, Khalid Izzeldin Elfatih Barakat, Khalid Osman Elamin Elsayed, MN Quraishi
Journal Crohn s & Colitis 360
Year 2026
DOI
10.1093/crocol/otag061
URL
https://doi.org/10.1093/crocol/otag061
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.